2023-05-03 07:05:57 ET
- BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q1 GAAP EPS of -$0.28 beats by $0.03 .
- Revenue of $68.78M (+37.8% Y/Y) misses by $2.66M .
- The increase was primarily due to $68.4 million in ORLADEYO net revenue in the first quarter of 2023, compared to $49.7 million in ORLADEYO net revenue in the first quarter of 2022 (+37.6 percent y-o-y).
-
Financial Outlook for 2023
The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. Operating expenses for full year 2023, not including non-cash stock compensation, are expected to be flat to 2022 at approximately $375 million. While flat year-over-year, we expect reductions in R&D spending in 2023 following the discontinuation of the BCX9930 and BCX9250 programs in 2022 and the delay in the BCX10013 clinical program, offset by increases in SG&A to support the U.S. launch and global expansion of ORLADEYO.
For further details see:
BioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66M